Key facts
- It has raised $32.6M; the latest was Early Stage VC ($10.0M) in Aug 2024.
- Notable investors include Gaingels, BlueYard Capital, JAZZ Venture Partners, Prototype Capital (San Francisco).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Transcripta Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Transcripta Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Transcripta Bio
Developer of an artificial intelligence-driven drug discovery platform designed for accelerating therapeutic development. The company's platform integrates experimentation and computation to generate high-resolution transcriptomic data, utilizes proprietary gene expression analytics, and synthesizes molecules for validation, enabling pharmaceutical researchers and clinicians to identify therapeutic opportunities across a wide range of human diseases and predict biological responses, thereby improving the efficiency and precision of drug discovery.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Employees
- 27
- Website
- transcriptabio.com/
- Ownership
- Privately Held (backing)
Transcripta Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Transcripta Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Transcripta Bio in its N-PORT filings yet. We sweep new filings monthly.